Dow Jones
39.112,16 -299,05 (-0,76%) Nasdaq
17.717,65 +220,84 (+1,26%) Nikkei 225
39.697,37 +524,22 (+1,34%) EUR/USD
1,0712 -0,0003 (-0,03%) Bitcoin EUR
57.794,18 +602,55 (+1,05%) CMC Crypto 200
1.283,94 +34,82 (+2,79%)
CRBP Jul 2024 40.000 call
| Chiusura precedente | 9,50 |
| Aperto | 9,50 |
| Denaro | 5,40 |
| Domanda | 7,60 |
| Prezzo d'esercizio | 40,00 |
| Scadenza | 2024-07-19 |
| Min-Max giorno | 9,50 - 9,50 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireCorbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotinEarly dose escalation clinical data supports differentiating features established pre-clinicallyThe company on schedule to initiate its US study in Q1-2024 NORWOOD, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next ge
- GlobeNewswire
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET. To register for the webinar, click here. The event will feature several Oncology experts Daniel P.
